FMP

FMP

Enter

Divi’s Laboratories (NSE: DIVISLAB) significantly outperformed expectations in its latest quarter, reporting an 18% year-over-year (YoY) increase in revenue and

Divi’s Laboratories Reports Strong Q4 Performance, Driven by Custom Synthesis Growth

-

twitterlinkedinfacebook
blog post cover photo

Image credit: National Cancer Institute

Divi's Laboratories (NSE: DIVISLAB) significantly outperformed expectations in its latest quarter, reporting an 18% year-over-year (YoY) increase in revenue and a 50% rise in EBITDA. This growth was largely driven by the Custom Synthesis (CS) segment, which saw a 38% quarter-over-quarter (QoQ) and 47% YoY increase, thanks to two major projects reaching full-scale production.

CS now contributes 51% of the revenue mix. Meanwhile, the generics segment declined by 5% YoY due to pricing pressures, despite volume gains. Divi's reported a margin (excluding other income) of 31.7%, 400 basis points above Goldman Sachs' (NYSE: GS) estimates.

Key Highlights:

  1. Commercialization of Kakinada Phase 1: Expected in the second half of FY25, freeing up capacity at existing units.
  2. Market Share Gains: Opportunities in key molecules like Carbidopa, Levodopa, and others where Divi's holds a substantial global share.
  3. Investments in New Areas: Growth from Peptides, Sartans, and Contrast media.
  4. Upcoming Patent Expirations: New generics going off-patent between 2025-2028, worth $20 billion.
  5. Unique Technology Projects: Long-term agreements with significant capital expenditure (INR 7 billion) for custom synthesis.

Financial Outlook:

Goldman Sachs raised its EPS estimates for FY25 to FY27 by up to 6% due to better topline performance and operating leverage benefits. The 12-month target price increased to INR 4,020 from INR 3,640. Despite this, Goldman Sachs maintains a Neutral rating due to balanced risk-reward considerations.

Explore Financial Ratios:

Discover how this sector is performing relative to others using the Sector PE Ratio API.


Other Blogs

Nov 25, 2023 6:39 AM - Parth Sanghvi

DCF Valuation vs. Comparable Companies Analysis: Choosing the Right Valuation Method

Choosing the Right Valuation Method: DCF vs. Comparable Companies Analysis Introduction: Valuation methods play a pivotal role in determining the fair value of a company, aiding investors in making informed investment decisions. Two commonly used methods, DCF Valuation and Comparable Companies A...

blog post title

Dec 23, 2023 2:19 AM - Parth Sanghvi

Understanding the Limitations of DCF Analysis: A Guide to Overcoming Challenges

Introduction: Discounted Cash Flow (DCF) analysis stands as a cornerstone in valuing investments, yet its efficacy is contingent upon various assumptions and methodologies. While a powerful tool, DCF analysis comes with inherent limitations and challenges that investors must acknowledge to make i...

blog post title

Dec 25, 2023 2:28 AM - Parth Sanghvi

Integrating Sustainability into Valuations: Navigating ESG Factors within the Discounted Cash Flow (DCF) Model

Introduction: The investment landscape is undergoing a profound shift with a heightened emphasis on sustainability and responsible investing. In this blog post, we explore the intersection of Environmental, Social, and Governance (ESG) considerations within the Discounted Cash Flow (DCF) model, h...

blog post title
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep